Trials / Conditions / Stage IV Verrucous Carcinoma of the Larynx

Stage IV Verrucous Carcinoma of the Larynx

19 registered clinical trials studyying Stage IV Verrucous Carcinoma of the Larynx.

Status	Trial	Sponsor	Phase
Completed	Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Sta NCT02048020	Jonsson Comprehensive Cancer Center	Phase 2
Terminated	Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443	AIDS Malignancy Consortium	Phase 1
Terminated	Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer NCT01254734	City of Hope Medical Center	N/A
Completed	Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr NCT01316757	Fox Chase Cancer Center	Phase 2
Terminated	Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck NCT01192815	Case Comprehensive Cancer Center	Phase 2
Terminated	Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radi NCT01164566	Wake Forest University Health Sciences	N/A
Completed	L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For NCT01155609	University of Washington	N/A
Completed	Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck NCT01044433	Abramson Cancer Center at Penn Medicine	Phase 2
Completed	Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cance NCT01637194	Fox Chase Cancer Center	Phase 1
Terminated	Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri NCT00492089	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384	National Cancer Institute (NCI)	Phase 1
Completed	Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell NCT00103259	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00095628	National Cancer Institute (NCI)	Phase 2
Completed	Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498	National Cancer Institute (NCI)	Phase 1
Completed	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959	National Cancer Institute (NCI)	Phase 1